X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding helps BioCorRx to focus on the clinical development of BICX104 (naltrexone) a biodegradable, long-acting subcutaneous pellet in combination with Bupropion. It is currently evaluated in preclinical studies for methamphetamine use disorder.
Lead Product(s): Naltrexone,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 28, 2024
Details:
The submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria.
Lead Product(s): Naltrexone,Magnesium Stearate API
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of OUD being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
BICX104, implantable subcutaneous naltrexone pellets and the marketed once-a-month intramuscular depot naltrexone injection for the treatment of opioid use disorder (OUD).
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
BICX104 is an eroding subcutaneous implantable pellet that contains 1 g naltrexone and 11 mg magnesium stearate that will be inserted subcutaneously. It will be administered once for 84 days.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
BICX104 is being developed in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002. Part of this supplemental grant will be used to develop and refine systems and strategies at BioCorRx.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $9.3 million Upfront Cash: Undisclosed
Deal Type: Funding April 11, 2022
Details:
The BICX104 clinical study in two parallel groups of 12 randomized healthy volunteers to evaluate the pharmacokinetics and safety of BICX104 implantable subcutaneous naltrexone pellets and the marketed once a month intramuscular depot naltrexone injection.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD). The company submitted the IND to the FDA last month. The first-in-human clinical trial.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed under BioCorRx Pharmaceuticals, Inc., BioCorRx’s controlled R&D subsidiary.
Lead Product(s): Naltrexone
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Societal CDMO
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
